Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes

Journal of Viral Hepatitis

Volumn 20, Issue 6, 2013, Pages 395-403

  De Meyer, S ^a   Ghys, A ^a   Foster, G R ^b   Beumont, M ^a   Van Baelen, B ^a   Lin, T I ^a   Dierynck, I ^a   Ceulemans, H ^a   Picchio, G ^c  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

drug resistance; genotype 2 and 3; hepatitis C; mutation; peginterferon alfa 2a; protease inhibitors; ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; MONOTHERAPY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MUTATION; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, PROTEIN; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84877580533     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12046     Document Type: Article

References (17)

1. Alter MJ,. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13 (17): 2436-2441.
2. Sarrazin C, Zeuzem S,. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138 (2): 447-462.
3. Bostan N, Mahmood T,. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010; 36 (2): 91-133.
4. Simmonds P,. Reconstructing the origins of human hepatitis viruses. Phil Trans R Soc Lond B 2001; 356 (1411): 1013-1026.
5. Esteban JI, Sauleda S, Quer J,. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48 (1): 148-162.
6. Lin K, Kwong AD, Lin C,. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004; 48 (12): 4784-4792.
7. Berman K, Kwo PY,. Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis 2009; 13 (3): 429-439.
8. Bacon BR, Gordon SC, Lawitz E, et al,. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1207-1217.
9. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1195-1206.
10. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
11. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365 (11): 1014-1024.
12. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364 (25): 2417-2428.
13. Lin C, Hanzelka BL, Müh U, et al,. Telaprevir (VX-950) is a potent inhibitor of HCV NS3 proteases derived from genotype non-1 HCV-infected patients. J Hepatol 2007; 46 (Suppl 1): S8.
14. Foster GR, Hézode C, Bronowicki J-P, et al,. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141 (3): 881-889.
15. Kieffer TL, Kwong AD, Picchio GR,. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65 (2): 202-212.
16. Sarrazin C, Kieffer TL, Bartels D, et al,. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132 (5): 1767-1777.
17. Qiu P, Sanfiorenzo V, Curry S, et al,. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 2009; 37 (10): e74.22.